全球小分子 CDMO 市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

全球小分子 CDMO 市場需求預計將從 2023 年的 682.3 億美元增加到 2032 年的近 1,379.8 億美元，2024-2032 年研究期間複合CAGR為 8.14%。

小分子合約開發和製造組織 (CDMO) 是提供與小分子藥物的開發、製造（有時包括測試）相關服務的公司。小分子通常是在藥物製劑中用作活性藥物成分的低分子量化合物。 CDMO 代表製藥和生技公司提供生產這些小分子藥物的專業知識和基礎設施。

市場動態

小分子合約開發和製造組織 (CDMO) 市場受到反映製藥業不斷變化的格局的幾個因素的推動。在對成本效率和專業知識的渴望的推動下，藥物開發和製造的外包趨勢不斷增加，這大大增加了對小分子 CDMO 服務的需求。小分子藥物開發的複雜性日益增加，加上藥物管道的增加，促使製藥公司尋求外部合作夥伴來進行化學合成、製程最佳化和監管合規。專注於核心能力、具成本效益的解決方案和藥品製造的全球化進一步推動市場。小分子 CDMO 提供靈活性、可擴展性和加速上市時間，吸引了希望有效應對藥物開發複雜階段的公司。技術進步和 CDMO 的監管專業知識也發揮關鍵作用，確保客戶能夠獲得最先進的解決方案並能夠無縫滿足監管要求。隨著製藥業的不斷發展，小分子 CDMO 市場預計將持續成長，從而塑造藥物開發和製造合作夥伴關係的格局。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球小分子 cdmo 市場的各個細分市場進行了包容性評估。小分子 cdmo 產業的成長和趨勢為本研究提供了整體方法。

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲小分子 CDMO 市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。小分子CDMO市場的主要參與者包括Lonza、Catalent, Inc.、Thermo Fisher Scientific Inc.、Cambrex Corporation、Bellen Chemistry、Siegfried Holding AG、Recipharm AB、Eurofins Scientific、Aurigene Pharmaceutical Services Ltd.、CordenPharma International。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

• 報告說明
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法論
  • 市場研究過程
  • 市場研究方法論

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：小分子 CDMO - 產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業動態
• 波特五力分析
• 市場吸引力分析
  • 按產品分類的市場吸引力分析
  • 按藥物類型分類的市場吸引力分析
  • 市場吸引力分析：依應用分類
  • 市場吸引力分析：按地區

第 4 章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料廠商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第 5 章：全球小分子 CDMO 市場分析：依產品分類

• 按產品概述
• 歷史和預測數據
• 按產品分析
• 活性藥物成分 (API)
• 藥品成品

第 6 章：全球小分子 CDMO 市場分析：依藥物類型

• 按藥物類型概述
• 歷史和預測數據
• 依藥物類型分析
• 創新者
• 泛型

第 7 章：全球小分子 CDMO 市場分析：依應用分類

• 概述：按應用
• 歷史和預測數據
• 分析：按應用
• 腫瘤學
• 心血管疾病
• 中樞神經系統 (CNS) 狀況
• 自體免疫/炎症
• 其他

第 8 章：全球小分子 CDMO 市場分析：依地理位置

• 區域展望
• 介紹
• 北美銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 北美按細分市場銷售分析
  • 北美按國家銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 歐洲按細分市場銷售分析
  • 歐洲按國家銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 亞太地區按細分市場銷售分析
  • 亞太地區國家/地區銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 東南亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 拉丁美洲按細分市場銷售分析
  • 拉丁美洲按國家銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 中東和非洲按細分市場銷售分析
  • 中東和非洲國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東其他地區和非洲銷售分析

第 9 章：小分子 CDMO 公司的競爭格局

• 小分子Cdmo市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第 10 章：公司簡介

• 公司股份分析
• 市場集中度
• Lonza
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Catalent Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Thermo Fisher Scientific Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Cambrex Corporation
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Bellen Chemistry
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Siegfried Holding AG
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Recipharm AB
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Eurofins Scientific
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Aurigene Pharmaceutical Services Ltd.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• CordenPharma International
• 公司簡介
• 公司收入
• 產品
• 最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

The global demand for Small Molecule CDMO Market is presumed to reach the market size of nearly USD 137.98 BN by 2032 from USD 68.23 BN in 2023 with a CAGR of 8.14% under the study period 2024 - 2032.

Small Molecule Contract Development and Manufacturing Organizations (CDMOs) are companies that provide services related to the development, manufacturing, and sometimes testing of small molecule drugs. Small molecules are typically low molecular weight compounds that are used as active pharmaceutical ingredients in drug formulations. CDMOs offer expertise and infrastructure for the production of these small molecule drugs on behalf of pharmaceutical and biotechnology companies.

MARKET DYNAMICS

The Small Molecule Contract Development and Manufacturing Organization (CDMO) market is propelled by several factors reflecting the evolving landscape of the pharmaceutical industry. Increasing outsourcing trends in drug development and manufacturing, driven by a desire for cost efficiency and specialized expertise, contribute significantly to the demand for Small molecule CDMO services. The growing complexity of small molecule drug development, coupled with the rise in drug pipelines, prompts pharmaceutical companies to seek external partners for chemical synthesis, process optimization, and regulatory compliance. Focus on core competencies, cost-effective solutions, and the globalization of pharmaceutical manufacturing further fuel the market. Small molecule CDMOs offer flexibility, scalability, and accelerated time-to-market, attracting companies looking to navigate the intricate stages of drug development efficiently. Technological advancements and the CDMOs' regulatory expertise also play pivotal roles, ensuring clients have access to state-of-the-art solutions and can navigate regulatory requirements seamlessly. As the pharmaceutical industry continues to evolve, the Small molecule CDMO market is expected to witness sustained growth, shaping the landscape of drug development and manufacturing partnerships.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of small molecule cdmo. The growth and trends of small molecule cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the small molecule cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• Active Pharmaceutical Ingredients (API)
• Finished Drug Products

By Drug Type

• Innovators
• Generics

By Application

• Oncology
• Cardiovascular Disease
• Central Nervous System (Cns) Conditions
• Autoimmune/Inflammation
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Small Molecule CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Small Molecule CDMO market include Lonza, Catalent, Inc., Thermo Fisher Scientific Inc., Cambrex Corporation, Bellen Chemistry, Siegfried Holding AG, Recipharm AB, Eurofins Scientific, Aurigene Pharmaceutical Services Ltd., CordenPharma International. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . SMALL MOLECULE CDMO - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Drug Type
  • 3.7.3 Market Attractiveness Analysis By Application
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL SMALL MOLECULE CDMO MARKET ANALYSIS BY PRODUCT

• 5.1 Overview by Product
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Product
• 5.4 Active Pharmaceutical Ingredients (API) Historic and Forecast Sales by Regions
• 5.5 Finished Drug Products Historic and Forecast Sales by Regions

6 . GLOBAL SMALL MOLECULE CDMO MARKET ANALYSIS BY DRUG TYPE

• 6.1 Overview by Drug Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Drug Type
• 6.4 Innovators Historic and Forecast Sales by Regions
• 6.5 Generics Historic and Forecast Sales by Regions

7 . GLOBAL SMALL MOLECULE CDMO MARKET ANALYSIS BY APPLICATION

• 7.1 Overview by Application
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Application
• 7.4 Oncology Historic and Forecast Sales by Regions
• 7.5 Cardiovascular Disease Historic and Forecast Sales by Regions
• 7.6 Central Nervous System (CNS) Conditions Historic and Forecast Sales by Regions
• 7.7 Autoimmune/Inflammation Historic and Forecast Sales by Regions
• 7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL SMALL MOLECULE CDMO MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE SMALL MOLECULE CDMO COMPANIES

• 9.1. Small Molecule Cdmo Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF SMALL MOLECULE CDMO INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Lonza
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Catalent Inc.
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Thermo Fisher Scientific Inc.
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Cambrex Corporation
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Bellen Chemistry
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. Siegfried Holding AG
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. Recipharm AB
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Eurofins Scientific
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Aurigene Pharmaceutical Services Ltd.
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. CordenPharma International
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Product (USD MN)
• Active Pharmaceutical Ingredients (API) Market Sales by Geography (USD MN)
• Finished Drug Products Market Sales by Geography (USD MN)
• Analysis Market by Drug Type (USD MN)
• Innovators Market Sales by Geography (USD MN)
• Generics Market Sales by Geography (USD MN)
• Analysis by Application (USD MN)
• Oncology Market Sales by Geography (USD MN)
• Cardiovascular Disease Market Sales by Geography (USD MN)
• Central Nervous System (CNS) Conditions Market Sales by Geography (USD MN)
• Autoimmune/Inflammation Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Small Molecule Cdmo Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Small Molecule Cdmo Report
• Market Research Process
• Market Research Methodology
• Global Small Molecule Cdmo Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Product
• Market Attractiveness Analysis by Drug Type
• Market Attractiveness Analysis by Application
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Product (USD MN)
• Active Pharmaceutical Ingredients (API) Market Sales by Geography (USD MN)
• Finished Drug Products Market Sales by Geography (USD MN)
• Global Market Analysis by Drug Type (USD MN)
• Innovators Market Sales by Geography (USD MN)
• Generics Market Sales by Geography (USD MN)
• Global Market Analysis by Application (USD MN)
• Oncology Market Sales by Geography (USD MN)
• Cardiovascular Disease Market Sales by Geography (USD MN)
• Central Nervous System (CNS) Conditions Market Sales by Geography (USD MN)
• Autoimmune/Inflammation Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.